Study on the safety of remidazolam toluenesulfonate combined with sufentanil in painless ultrasonic gastroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069412

Enrollment

Unknown

Registered

2023-03-15

Start date

2023-03-22

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Rima Group:Remazolam toluenesulfonate administered

Propofol group:Administration of propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. ASA grade I-III, 2. BMI 18-30 kg/m2; 3. Aged 18-65 years; 4. Planned painless endoscopic ultrasonography; 5. Informed consent of patients and their families to the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Long-term alcoholism and tolerance to narcotic drugs; 2. People who are allergic to drugs used in this study; 3. Drinking and fasting for less than 8 hours; 4. Patients with long-term pain and anxiety; 5. Patients with oxygen saturation = 180/110 mmHg (WHO-ISH hypertension guideline grade 3 hypertension); 8. Patients with a history of gastrointestinal surgery; 9. Patients participating in other studies within 30 days; 10. Patients can't cooperate; 11. Liver dysfunction (Child-Pugh grade C or above), acute upper gastrointestinal hemorrhage with shock, severe anemia.

Design outcomes

Primary

Measure	Time frame
Incidence of hypotension;	—

Secondary

Measure	Time frame
Hypoxemia incidence;Incidence rate of adverse events;	—

Countries

China

Contacts

Public ContactJiang Ke

The Affiliated Hospital of Guizhou Medical University

348697044@qq.com+86 18096001863

Outcome results